Teva Pharmaceutical Industries (NYSE:TEVA) Given New $30.00 Price Target at UBS Group

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective lifted by UBS Group from $28.00 to $30.00 in a research report sent to investors on Thursday morning,Benzinga reports. UBS Group currently has a buy rating on the stock.

Several other research firms also recently weighed in on TEVA. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler increased their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Finally, Barclays upped their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.63.

Teva Pharmaceutical Industries Stock Down 0.3 %

TEVA opened at $21.74 on Thursday. The company has a market cap of $24.62 billion, a PE ratio of -25.57, a price-to-earnings-growth ratio of 1.11 and a beta of 0.73. Teva Pharmaceutical Industries has a twelve month low of $11.48 and a twelve month high of $22.80. The company has a 50-day moving average price of $19.74 and a 200 day moving average price of $18.40. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Insider Activity

In related news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently modified their holdings of the business. Coronation Fund Managers Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter valued at about $1,334,000. American Century Companies Inc. boosted its position in shares of Teva Pharmaceutical Industries by 12.9% during the 2nd quarter. American Century Companies Inc. now owns 175,178 shares of the company’s stock worth $2,847,000 after purchasing an additional 20,026 shares during the period. Dimensional Fund Advisors LP increased its holdings in Teva Pharmaceutical Industries by 23.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,466,704 shares of the company’s stock valued at $23,834,000 after purchasing an additional 274,891 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its position in Teva Pharmaceutical Industries by 26.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 27,643 shares of the company’s stock valued at $449,000 after purchasing an additional 5,831 shares during the period. Finally, Thrivent Financial for Lutherans lifted its stake in Teva Pharmaceutical Industries by 44.1% during the second quarter. Thrivent Financial for Lutherans now owns 184,293 shares of the company’s stock worth $2,995,000 after purchasing an additional 56,388 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.